Naomi Givens

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

Jean‐Michel Molina, Bonaventura Clotet, Jan van Lunzen et al. · The Lancet HIV · 2015 · 223 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study

Frank A. Post, Graeme Moyle, Hans Jürgen Stellbrink et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 218 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Psychiatric Symptoms in Patients Receiving Dolutegravir

Anna Fettiplace, Chris Stainsby, Alan Winston et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2016 · 101 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Dolutegravir versus Placebo in Subjects Harbouring HIV-1 with Integrase Inhibitor Resistance Associated Substitutions: 48-Week Results from VIKING-4, a Randomized Study

Bisher Akil, Gary Blick, Debbie Hagins et al. · Antiviral Therapy · 2014 · 78 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Once‐daily dolutegravir is superior to once‐daily darunavir/ritonavir in treatment‐naïve HIV‐1‐positive individuals: 96 week results from FLAMINGO

Jean‐Michel Molina, Bonaventura Clotet, Jan van Lunzen et al. · Journal of the International AIDS Society · 2014 · 52 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15